by Charles Bankhead – MedPageToday –
Long-term survival in the CARTITUDE-1 trial showed that almost half of patients remained, alive with a median overall survival (OS) of 60.7 months. Almost three-fourths of the survivors remained progression free, and more than a fourth had undetectable disease.
Treated only with a single infusion of ciltacabtagene autoleucel (cilta-cel, Carvykti) CAR T-cell therapy, the patients’ “remarkable” clinical course suggested “a potential cure, or at bare minimum, unprecedented durability of complete response,” said Peter Voorhees, MD, of Wake Forest School of Medicine in Charlotte, North Carolina, at the American Society of Clinical Oncology (ASCO) meeting.
